openPR Logo
Press release

Infliximab Biosimilar Insight, 2022 | DelveInsight

06-06-2022 08:09 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Infliximab Biosimilar

Infliximab Biosimilar

DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Interested to know more about the functioning of Biosimilars, visit @ https://www.delveinsight.com/report-store/infliximab-biosimilars-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Geography Covered: Global coverage

Infliximab: Overview

Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet's disease.

Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α 1, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α 1

Request for a detailed sample copy of our report @ https://www.delveinsight.com/sample-request/infliximab-biosimilars-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Infliximab Biosimilars: Marketed Drugs
1. Inflectra: Celltrion/Pfizer
2. Renflexis: Merck
Infliximab Biosimilars: Emerging Drugs
1. BCD 055: Biocad
2. CT-P17: Celltrion
Major Players in Infliximab

There are approximately 20+ Infliximab biosimilars key companies which are developing the therapies for Infliximab.

To understand key companies related to the Infliximab Biosimilars Market, get a snapshot @ https://www.delveinsight.com/report-store/infliximab-biosimilars-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Infliximab Biosimilars Report Highlights:
1. The companies and academics are working to assess challenges and seek opportunities that could influence Infliximab R&D. The therapies under development are focused on novel approaches to treat/improve Infliximab.
2. In July 2017, Merck had launched in the U.S. a biosimilar of Remicade (infliximab), the blockbuster immune-mediated inflammatory disorders treatment it markets outside the U.S., including Europe, while partner Janssen Biotech markets the drug stateside.
3. In December 2017, Pfizer announced that the United States (U.S.) Food and Drug Administration (FDA) has approved IXIFI (PF-06438179, infliximab-qbtx), a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor, as a biosimilar to Remicade (infliximab) for all eligible indications of the reference product. The FDA has approved IXIFI as a treatment for patients with rheumatoid arthritis, Crohn's disease, pediatric Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

For detailed Infliximab Biosimilars Report Highlights, visit here @ https://www.delveinsight.com/report-store/infliximab-biosimilars-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents:

1. Key Insights
2. Infliximab Biosimilars: Snapshot
3. Executive Summary
4. Regulatory Outlook For Biosimilars
5. Infliximab (Reference Product: Remicade)
6. Research and Development
7. Remicade Biosimilar: Emerging Opportunities
8. Infliximab: Biosimilars Assessment
9. Infliximab Biosimilars Profiles: By Company
10. Infliximab Biosimilars: Comparative Landscape: By Company
11. Infliximab Biosimilars: Competitive Landscape
12. Market Drivers
13. Market Barriers
14. SWOT Analysis
15. Appendix
16. Bibliography
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

Reqest for a detailed TOC of the Infliximab Biosimilars Report @ https://www.delveinsight.com/sample-request/infliximab-biosimilars-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Us:

Kritika Rehani
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Infliximab Biosimilar Insight, 2022 | DelveInsight here

News-ID: 2645046 • Views:

More Releases from DelveInsight Business Research

Hidradenitis Suppurativa Market is expected to sour at a CAGR of 13.5%, as per DelveInsight | HUMIRA, COSENTYX (secukinumab), BIMZELX (bimekizumab), and others.
Hidradenitis Suppurativa Market is expected to sour at a CAGR of 13.5%, as per D …
(Albany, USA) DelveInsight's "Hidradenitis Suppurativa Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Hidradenitis Suppurativa market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Hidradenitis Suppurativa
Synovial Sarcoma Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, ROA, and Companies by DelveInsight | CFT 8634, FHD 609, BA-3011, more
Synovial Sarcoma Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapi …
(Albany, USA) As per DelveInsight's assessment, globally, about 14+ key pharma and biotech companies are working on 14+ pipeline drugs in the Synovial Sarcoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Synovial Sarcoma Pipeline Insight, 2024" report by DelveInsight provides a
Breast Cancer Pipeline Assessment 2024: FDA, EMA, PDMA Approvals, Clinical Trials, Drugs, Mechanism of Action, Route of Administration and Companies by DelveInsight
Breast Cancer Pipeline Assessment 2024: FDA, EMA, PDMA Approvals, Clinical Trial …
(Albany, United States) As per DelveInsight's assessment, globally, Breast Cancer pipeline constitutes 120+ key companies continuously working towards developing 130+ Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Breast Cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Breast Cancer Market. The Breast Cancer Pipeline report embraces in-depth commercial
Overactive Bladder Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, ROA, and Companies by DelveInsight | Neuronox, URO-902, more
Overactive Bladder Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Thera …
(Albany, USA) As per DelveInsight's assessment, globally, about 15+ key pharma and biotech companies are working on 15+ pipeline drugs in the Overactive Bladder therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Overactive Bladder Pipeline Insight, 2024" report by DelveInsight provides a

All 5 Releases


More Releases for Infliximab

Global Infliximab and Biosimilar Market Analysis during 2022-2028
The global infliximab and biosimilar market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The infliximab is a monoclonal anti-tumor necrosis antibody used to treat certain types of arthritis (rheumatoid arthritis, psoriatic arthritis), certain bowel diseases (Crohn's disease and ulcerative colitis), and serious skin disease (chronic plaque psoriasis). Biosimilar is a medicine that is close in structure and function to a biological drug. The rise
Infliximab and Biosimilar Market 2021 | Detailed Report
Infliximab and Biosimilar Market Forecasts report provided to identify significant trends, drivers, influence factors in global and regions, agreements, new product launches and acquisitions, Analysis, market drivers, opportunities and challenges, risks in the market, cost and forecasts to 2027. Get Free Sample PDF (including full TOC, Tables and Figures) of Infliximab and Biosimilar Market @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5048518 The report provides a comprehensive analysis of company profiles listed below: - Janssen Biotech - Merck and
Adalimumab, Infliximab And Etanercept Biosimilars Market 2021 Segmentation, Futu …
New year, new updates! Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports The global adalimumab, infliximab and etanercept biosimilars market is expected to grow from $2.21 billion in 2020 to $3.02 billion in 2021 at a compound annual growth rate (CAGR) of 36.7%. The growth is mainly due to the companies resuming their operations and adapting to the new
Infliximab Market Report Analysis With Industry Share Published by Leading Resea …
Biosimilars are biological products that are similar to FDA-approved drug known as branded drug. Biosimilars are drugs licensed by the European Medicines Agency (EMA) and the U.S. FDA. These do not have significant differences from the reference products in terms of purity, effectiveness, and safety. Biosimilar drugs can only be permitted for conditions and indications that have been formerly accepted for the reference product by government regulatory agencies and organizations,
Impact of COVID-19 on Infliximab Market
Biosimilars are biological products that are similar to FDA-approved drug known as branded drug. Biosimilars are drugs licensed by the European Medicines Agency (EMA) and the U.S. FDA. These do not have significant differences from the reference products in terms of purity, effectiveness, and safety. Biosimilar drugs can only be permitted for conditions and indications that have been formerly accepted for the reference product by government regulatory agencies and organizations,
Infliximab Market - Analysis and Forecast 2018 - 2026 Explored in Latest Researc …
Biosimilars are biological products that are similar to FDA-approved drug known as branded drug. Biosimilars are drugs licensed by the European Medicines Agency (EMA) and the U.S. FDA. These do not have significant differences from the reference products in terms of purity, effectiveness, and safety. Biosimilar drugs can only be permitted for conditions and indications that have been formerly accepted for the reference product by government regulatory agencies and organizations,